737 related articles for article (PubMed ID: 28718672)
1. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
2. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
Kumar A; Kumar B; Bhatia R
Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
[TBL] [Abstract][Full Text] [Related]
6. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-arylaminoquinazolines bearing
Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
[TBL] [Abstract][Full Text] [Related]
9. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
11. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
El-Azab AS; Abdel-Aziz AA; AlSaif NA; Alkahtani HM; Alanazi MM; Obaidullah AJ; Eskandrani RO; Alharbi A
Bioorg Chem; 2020 Nov; 104():104345. PubMed ID: 33142413
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, and docking studies of some fused-quinazolines and quinazolines carrying biological active isatin moiety as cell-cycle inhibitors of breast cancer cell lines.
Radwan AA; Alanazi FK; Al-Dhfyan A
Drug Res (Stuttg); 2013 Mar; 63(3):129-36. PubMed ID: 23444171
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
[No Abstract] [Full Text] [Related]
16. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
18. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
19. The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds.
Guo H; Diao QP
Curr Top Med Chem; 2020; 20(16):1499-1503. PubMed ID: 32156238
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]